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Abstract
Background: The paired homeobox protein Pax6 is essential for proliferation and pluripotency
of retinal progenitors. However, temporal changes in Pax6 protein expression associated with the
generation of various retinal neurons have not been characterized with regard to the cell cycle.
Here, we examine the dynamic changes of Pax6 expression among chicken retinal progenitors as
they progress through the neurogenic cell cycle, and determine the effects of altered Pax6 levels
on retinogenesis.
Results: We provide evidence that during the preneurogenic to neurogenic transition, Pax6
protein levels in proliferating progenitor cells are down-regulated. Neurogenic retinal progenitors
retain a relatively low level of Pax6 protein, whereas postmitotic neurons either elevate or
extinguish Pax6 expression in a cell type-specific manner. Cell imaging and cell cycle analyses show
that neurogenic progenitors in the S phase of the cell cycle contain low levels of Pax6 protein,
whereas a subset of progenitors exhibits divergent levels of Pax6 protein upon entering the G2
phase of the cell cycle. We also show that M phase cells contain varied levels of Pax6, and some
correlate with the onset of early neuronal marker expression, forecasting cell cycle exit and cell
fate commitment. Furthermore, either elevating or knocking down Pax6 attenuates cell
proliferation and results in increased cell death. Reducing Pax6 decreases retinal ganglion cell
genesis and enhances cone photoreceptor and amacrine interneuron production, whereas
elevating Pax6 suppresses cone photoreceptor and amacrine cell fates.
Conclusion: These studies demonstrate for the first time quantitative changes in Pax6 protein
expression during the preneurogenic to neurogenic transition and during the neurogenic cell cycle.
The results indicate that Pax6 protein levels are stringently controlled in proliferating progenitors.
Maintaining a relatively low Pax6 protein level is necessary for S phase re-entry, whereas rapid
accumulation or reduction of Pax6 protein during the G2/M phase of the cell cycle may be required
for specific neuronal fates. These findings thus provide novel insights on the dynamic regulation of
Pax6 protein among neurogenic progenitors and the temporal frame of neuronal fate
determination.
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Background
The Pax6 gene encodes an evolutionarily conserved paired
homeobox protein critically involved in eye development
and retinogenesis [1-5]. In both Drosophila  and verte-
brates, ectopic expression of Pax6 induces ectopic eyes or
lens [2,6,7], indicating an instructive role of Pax6 in ocu-
lar tissue determination. Genetic studies have demon-
strated that the dosages of Pax6 strongly impact the
formation and growth of ocular tissues. Homozygous or
heterozygous loss of function Pax6 mutants have either
no eye or small eye phenotypes [8-11]. Conversely,
increasing dosages of the Pax6 gene also lead to microph-
thalmia and malformed retinas [12,13]. Furthermore,
Pax6 is involved in pattern formation of the vertebrate
eye. Aberrant Pax6 expression results in malformation of
the anterior segment of the eye [5,14-16]. Pax6 expression
in the optic vesicle is required for establishing the naso-
temporal axis and the dorsal characteristics of the retina
[17], whereas Pax6 expressed in the distal optic cup recip-
rocally suppresses Pax2 in the optic stalk to establish the
optic cup/stalk boundary [18]. The complex roles of Pax6
in eye development are reflected by the existence of mul-
tiple enhancers that regulate the exquisite spatial and tem-
poral expression of Pax6 transcripts in neural and non-
neural ocular tissues [17,19-21].
Multiple Pax6 isoforms are encoded by the Pax6 gene in
vertebrates [22-24]. The canonical Pax6 and the Pax6(5a)
isoform, which contains amino acid residues encoded by
an alternatively spliced exon inserted within the paired
domain, are commonly found among various vertebrates
[22,23,25]. The mammalian Pax6 and Pax6(5a) isoforms,
and their corresponding Drosophila homologs encoded by
the eyeless and eyegone genes, exhibit distinct biological
activities. Both Pax6 and eyeless can induce ectopic eye
formation in the fly wing imaginal disc [2], whereas
Pax6(5a) and eyegone can elicit only cell proliferation but
not neuronal differentiation [26]. Similarly, in embryonic
mouse cortex, Pax6 influences both cell proliferation and
neuronal differentiation, but Pax6(5a) only affects prolif-
eration [27,28]. In mice missing the transcript Pax6(5a),
lens abnormalities and iris hypoplasia are observed, but
development of the neural retina remains largely normal
[29], suggesting that Pax6 is able to compensate for the
function of Pax6(5a) in the neural retina.
During mammalian central nervous system development,
multipotent progenitors undergo a transition from the
preneurogenic stage, when symmetrical divisions occur
and give rise to proliferative progeny, to the neurogenic
stage, during which a subset of progenitors withdraw from
the cell cycle and initiate neuronal differentiation. In the
cortex, reducing Pax6 expression levels affects the length
of the cell cycle and the progression from symmetrical to
asymmetrical division among cortical progenitors [30].
Furthermore, decreased Pax6 expression leads to deple-
tion of basal cortical progenitor and precocious neuronal
differentiation [31]. In the spinal cord, altering Pax6 levels
affects the expression of the proneural gene Ngn2 and the
timing of cell cycle exit [32].
In the vertebrate retina, multipotent progenitor cells give
rise to six major types of neurons and one type of glial cell
in a conserved temporal order [33-38]. At the onset of
retinogenesis, the central retinal progenitors enter the
neurogenic stage first, while the peripheral retina remains
in a preneural state [39]. When Pax6 is conditionally
ablated in the peripheral retina by using the Pax6 α cre
mouse, which encodes the Pax6 P0 promoter and the α
enhancer driving the expression of cre recombinase, pro-
genitor expansion is affected, resulting in a retina reduced
in size [40]. In addition, in the Pax6 α cre-mediated Pax6
conditional knockout mutant, peripheral retinal progeni-
tors are unable to express multiple neurogenic basic helix-
loop-helix (bHLH) transcriptional factors and are limited
to producing only amacrine interneurons [40]. Recently,
it has been reported that Pax6 α cre-mediated Pax6 dele-
tion in the peripheral retina unmasks a suppression of the
cone-rod homeobox gene Crx by Pax6, and more centrally
localized Pax6 deletion by the Chx10-cre driver also leads
to the loss of progenitor multipotency [41]. Thus, Pax6
differentially expressed by the central or peripheral retinal
progenitor pools may serve distinct functions during
development, but nonetheless is required for generation
of multiple retinal neurons.
In the mature retina, various neuronal cell types express
disparate levels of Pax6. How this highly differential Pax6
expression is achieved among specific neurons remains
unclear. In this study, we have analyzed Pax6 expression
at the cellular level among neurogenic progenitors in the
embryonic chicken retina. We demonstrate a significant
down-regulation of Pax6 protein as progenitors undergo
the preneurogenic to neurogenic transition. In addition,
we show that while neurogenic progenitors maintain a
uniformly low Pax6 level during the S phase, a subset of
retinal progenitors rapidly increase or decrease their Pax6
levels as they enter G2/M phase of the cell cycle. The diver-
gence of Pax6 protein levels correlate with the onset of dif-
ferentiation for certain neurons. Moreover, disruption of
Pax6 levels among neurogenic progenitor cells leads to
aberrant proliferation and production of neuronal cell
types. These results reveal for the first time the dynamic
expression of Pax6 during the neurogenic cell cycle and
highlight the importance of Pax6 protein regulation as
neural progenitors adapt to different cell fates.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Results
Dynamic Pax6 expression during retinogenesis
Pax6 mRNA expression in the chicken optic primordium
initially begins at Hamburger and Hamilton (HH) stage
8.5 and persists at high levels throughout optic vesicle for-
mation and optic cup morphogenesis [42]. At the onset of
retinal neurogenesis at HH stage 17 [43], the expression of
Pax6 protein in the central retina begins to decrease
among progenitor cells. By HH stage 20, the central retina
undergoing active neurogenesis showed significantly
lower levels of Pax6 compared to the peripheral retina,
and this change in the levels of Pax6 correlated with the
propagation of the neurogenic wave, as demarcated by the
emergence of NF145-positive neurons (Figure 1A–C). At
the peak of retinal ganglion cell (RGC) genesis at embry-
onic day (E)6.5 (HH stage 30), the ventricular zone occu-
pied by proliferative progenitor cells contained low levels
of Pax6, whereas postmitotic RGCs exhibited a high level
of Pax6 expression (Figure 1D). The subsequently pro-
duced amacrine cells also showed high Pax6 levels at E7
(HH stage 32; Figure 1E). By E12 (HH stage 38), when
retinogenesis was near completion, amacrine cells, RGCs
and horizontal cells displayed distinct levels of Pax6, in
contrast to the absence of Pax6 from the photoreceptor
cells and the bipolar cells (Figure 1F).
To further characterize Pax6 protein levels in retinal pro-
genitor cells and postmitotic neurons, we performed
immunolabeling and flow cytometric analyses. Quantifi-
cation revealed that average Pax6 signal intensity of cells
residing in the peripheral halves of the retina was 1.7-fold
of that found in the neurogenic central retina at HH stage
25 (Figure 1G). Quantitative measurements of Pax6
between HH stages 30 and 32 showed that the total retinal
cell population existed as three distinct populations based
on their Pax6 protein levels (Figure 2C, left panel). Simi-
larly, cell distribution based on DNA content measure-
ments also revealed three cell populations with distinct
levels of Pax6 among G0/G1 cells with 2n DNA contents
(Figure 2C, right panel). Based on cell density profiles of
G0/G1 cells with distinct Pax6 signal levels, we delineated
the boundaries between the three cell populations and
designated these populations as: high Pax6 (Pax6Hi), low
Pax6 (Pax6Lo), and no Pax6 (Pax6Neg) cells (Figure 2C).
The majority of Pax6Hi and Pax6Neg cells had 2n DNA con-
tent and, therefore, were either G0 or G1 cells (Figure 2C;
Additional file 1). The Pax6Lo cells represented the largest
population of cells (46.5% of total cells) at this stage (Fig-
ure 2C) and were distributed throughout the cell cycle
(Figure 2C, right panel), indicating that Pax6Lo cells were
the proliferating progenitor cells. Immunolabeling of ret-
inal sections showed that progenitor cell marker prolifer-
ating cell nuclear antigen (PCNA)-labeled cells were
absent from the ganglion cell layer and exclusively distrib-
uted in the ventricular zone, where Pax6Lo cells resided
(Figure 2A). In addition, flow cytometry showed that
PCNA+ progenitor cells were also distributed throughout
the cell cycle (Figure 2B), supporting that Pax6Lo cells were
progenitor cells. In contrast, Pax6Hi cells were mostly co-
labeled with cells positive for the neuronal markers
NF145 or NF68 (Figure 2D,D',D",H) the RGC marker
Brn3a (Figure 2E,I), and the amacrine cell marker AP2α
(Figure 2F,J), whereas most Pax6Neg cells were positively
labeled with the early cone photoreceptor marker Visinin
(Figure 2G,K) and a small subset was NF+ (Figure 2D",H).
Together, these results demonstrate that Pax6 expression
in the retina decreases as progenitor cells undergo the pre-
neurogenic to neurogenic transition. Moreover, most neu-
rogenic retinal progenitors maintain low levels of Pax6,
whereas postmitotic neurons undergo cell type-specific
elevation or reduction of Pax6.
Cell cycle-dependent Pax6 protein expression among 
neurogenic progenitor cells
To examine when Pax6 levels change to result in the dis-
tinct Pax6 levels detected among postmitotic neurons, we
monitored progression of Pax6 expression among progen-
itors following bromodeoxyuridine (BrdU) pulse labe-
ling. Confocal imaging analyses showed that immediately
after a 20-minute BrdU incubation, BrdU-positive cells
were exclusively located within the middle stratum of the
E6.5 (HH stage 30) retina, representing progenitor cells in
the S phase of the cell cycle (Figure 3A). Most BrdU-
labeled cells co-expressed low levels of Pax6 and none
were detected in the outer one-third of the retina (Figure
3A,D). Within 30 minutes after the BrdU pulse, a few
BrdU-positive cells began to appear in the ventricular sur-
face (Figure 3B,E) and showed very low or no detectable
Pax6 protein (Figure 3E). By 60 minutes after BrdU labe-
ling, increasing numbers of BrdU-positive cells had
reached the outer one-third of the retina (Figure 3C,F).
Co-labeling of the M phase marker phospho-histone 3
(PH3) and BrdU was not detected at 30 minutes (Figure
3G,G') but was clearly visible at the ventricular surface 60
minutes after the BrdU pulse (Figure 3H,H'). These data
indicate that the G2 phase of the cell cycle was as short as
60 minutes at this developmental stage. The detection of
BrdU+ and Pax6Neg cells at the ventricular surface at 30
minutes indicated that a subset of Pax6Lo progenitor cells
had begun to down regulate Pax6 protein as early as the
G2 phase of the cell cycle.
To confirm the confocal imaging results, we performed
flow cytometry to analyze cellular Pax6 levels during S to
G2/M progression. Immediately after 20-minute BrdU
pulse labeling, BrdU+ cells were clustered in S phase (with
DNA content ranging between 2n and 4n) and showed
fairly uniform levels of Pax6Lo expression; whereas BrdU-
cells were distributed in G1/G0 phase (2n DNA content)Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Expression patterns of Pax6 in the developing chicken retina Figure 1
Expression patterns of Pax6 in the developing chicken retina. (A-G) Expression of Pax6 protein during the preneuro-
genic to neurogenic transition (A-C, G) and subsequent neurogenesis (D-F). (A-C) Immunofluorescent images of E4.5 (HH 
stage 24) retinas labeled for Pax6 (A), NF145 (B), and the merge of the two (C). White arrowheads in (B, C) indicate the neu-
rogenic wave front. (D-F) Immunohistochemical images of E6.5 (HH stage 30) (D), E7 (HH stage 32) (E), and E12 (HH stage 38) 
(F) retinas. ac, amacrine cells; bc, bipolar cells; c, central retina; gcl, ganglion cell layer; hc, horizontal cells; inl, inner nuclear 
layer; ipl, inner plexiform layer; onl, outer nuclear layer; p, peripheral retina; ret, retina; rpe, retinal pigment epithelium; vz, ven-
tricular zone. Scale bars: 100 μm; scale bar in (A) applies to (A-C), and in (D) to (D-F). (G) Quantification of Pax6 protein lev-
els in the preneurogenic and neurogenic regions. E4.5 (HH stage 25) eyes were cut at the equator to separate the central and 
peripheral portions. Dissociated retinal cells from the two portions were subjected to flow cytometric analyses to quantify 
Pax6 protein on a per cell basis. A representative cell distribution profile with regard to Pax6 levels is shown on the left. Aver-
age Pax6 levels for the central and peripheral retinal cells (N = 3, mean ± standard error) are shown on the right. Green, cen-
tral; red, peripheral. ***P < 0.001.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
Page 5 of 19
(page number not for citation purposes)
Distinct Pax6 expression levels among progenitors and postmitotic neurons Figure 2
Distinct Pax6 expression levels among progenitors and postmitotic neurons. Immunocytochemical and flow cyto-
metric analyses of neurogenic retinas. (A) Merged confocal image of PCNA (red) and Pax6 (green) co-labeled E6.5 (HH stage 
30) retina. (B) Flow cytometry profile of E6 retinal cells based on PCNA signal and DNA content. The positions of 2n and 4n 
DNA contents indicate cells residing in the G1/G0 (2n) or G2/M (4n) phase. S phase cells are positioned between 2n and 4n 
along the DNA content axis. PCNA+ cells (boxed, 83.2% of total cells) are distributed throughout the cell cycle. (C) Flow 
cytometry profiles for Pax6 levels of total cells (left panel) and Pax6 versus DNA content (right panel) at E7 (HH stage 32). 
Blue lines delineate Pax6Hi (20.9%), Pax6Lo (46.5%), and Pax6Neg (32.6%) cell popuations. (D-G) Merged confocal images of E6.5 
(HH stage 30) retinas co-labeled for Pax6 and NF145 (D), Brn3a (E), AP2α (F), or Visinin (G). (D', D") Higher magnification 
images of NF145 and Pax6 co-labeling near the ventricular surface. Arrows indicate co-labeled cells. Arrowheads point to 
marker-positive but Pax6-negative cells. (H-K) Flow cytometry profiles of Pax6 and NF68 (H), Brn3a (I), AP2α (J), and Visinin 
(K) at E7 (HH stage 32). Boxed regions delineate distribution of neuronal marker-positive cells according to Pax6 levels. Per-
centages of marker-positive cells among total cells are shown above the boxes. gcl, ganglion cell layer; vs, ventricular surface; vz, 
ventricular zone. Scale bars: 100 μm in (A, G), which applies to (D-G); 50 μm in (D'), which applies to (D', D").Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Pax6 expression during S, G2 and M phase of the cell cycle Figure 3
Pax6 expression during S, G2 and M phase of the cell cycle. Merged confocal immunofluorescent images of E6.5 (HH 
stage 30) retinas after a 20-minute bromodeoxyuridine (BrdU) pulse label in vitro. (A-F) Co-staining of BrdU and Pax6 at 0 (A, 
D), 30 (B, E), and 60 minutes (C, F) after the pulse label. The boxed regions in (A-C) are shown in (D-F), respectively, at two-
fold magnification. Note the appearance of BrdU+ cells at the ventricular surface by the 30-minute chase time. (G, G', H, H') 
Co-staining of phospho-histone 3 (PH3) and Pax6 at 30 (G, G') or 60 minutes (H, H') after the pulse label. The boxed regions 
in (G, H) are shown as separate panels in (G', H'), respectively, at twofold magnification. Note the appearance of BrdU+PH3+ 
double-labeled cells at the ventricular surface by the 60-minute chase time. Arrows indicate BrdU and PH3 co-labeled cells. 
Arrowheads point to BrdU+ cells. gcl, ganglion cell layer; vs, ventricular surface; vz, ventricular zone. Scale bar: 100 μm; the 
scale bar in (A) applies to (A-C, G, H).Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Figure 4 (see legend on next page)Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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and G2/M phase (4n DNA content) as expected (Figure
4A, 0 hour column). At 3 hours post labeling, the cohort
of BrdU+ cells appeared in the 4n DNA content territory
(Figure 4A, 3 hour column). By 6 hours post BrdU labe-
ling, increasing numbers of BrdU+ cells appeared in G2/M
phase; in addition, a fraction of the BrdU+ cells clearly
possessed 2n DNA content, indicating that they had com-
pleted M phase and entered G1 or G0 phase (Figure 4A, 6
hour column). Between 6 and 12 hours after pulse labe-
ling, the BrdU+ population continued to accumulate in
the G1/G0 phase and decrease in the S phase, reflecting
progression of the initial BrdU-labeled cohort.
We next quantified changes of Pax6 protein levels during
the transition from the S phase to G2/M phase of the cell
cycle. In the E6.5 (HH stage 30) retina when RGC produc-
tion peaks, following a 20-minute BrdU pulse, an average
of 10.7% of the cells were labeled by BrdU (Figure 4B).
After a 3 or 6 hour chasing period, BrdU+Pax6Hi cells grad-
ually increased in the G2/M phase population (17% of
total cells, with 4n DNA content) compared to the uni-
form Pax6Lo level of the 0 hour BrdU+ cells (Figure 4B).
Quantification of Pax6 levels among 4n BrdU+  cells
showed a steady increase of BrdU+Pax6Hi cells (Figure 4C).
At 30 minutes after the pulse chase, the BrdU+Pax6Hi cell
population already showed a statistically significant
increase (Figure 4C). After 6 hours of chase, the percent-
age of BrdU+Pax6Hi cells had increased from 7.0% to
20.8% (Figure 4C; N = 3). Concomitantly, the Pax6Lo pro-
genitor cells decreased from 87.6% to 72.5% during the 6
hour chase period (Figure 4C; N = 3), reflecting altered
Pax6 expression as progenitors progressed through the
G2/M phase. However, the Pax6Neg cell populations did
not show statistically significant changes during the chase
(Figure 4C).
In order to monitor changes in Pax6 protein levels among
progenitors during the entire cell cycle, we excluded post-
mitotic G0 cells by labeling with a combination of availa-
ble neuronal markers, including Brn3a, Islet1/2, AP2α,
and Visinin (Figure 5A). As expected, most postmitotic G0
cells positively labeled for combined neuronal markers at
E7 (HH stage 32) exhibited either Pax6Neg (Figure 5B, gate
a) or Pax6Hi profiles (Figure 5B, gate c). To identify S phase
cells, we also pulse-labeled E7 cells with BrdU. Profiling of
BrdU+ cells showed that S phase cells contained low Pax6
levels (Figure 5B, gate b; and data not shown). We then
defined the G1 and G2/M cells (Figure 5B, gate d) by
exclusion of both neuronal marker-positive G0 phase cells
and BrdU+ S phase cells from the total cell population
(Figure 5B). DNA content analyses further separated G1
and G2/M cell populations and demonstrated that G1
cells and G2/M cells exhibited a broader range of Pax6
protein levels than S phase cells (Figure 5C–E). These data
again demonstrate the divergence of Pax6 levels after the
S to G2/M phase transition. Furthermore, an increased
Pax6Neg cell population was detected in the G2/M phase,
corresponding to the peak production of cone photore-
ceptors at E7. These results also indicate that progenitors
in the G1 phase of the cell cycle show divergent Pax6
expression, which becomes more restricted upon S phase
entry.
Divergent Pax6 expression in G2/M and neuronal fate 
specification
To determine if the divergence of Pax6 levels in G2/M was
correlated with progenitor cell behaviors, we performed
double immunocytochemistry of Pax6 and neuronal cell
markers. At E6.5 (HH stage 30) double labeling of Pax6
and the M phase marker PH3 showed that PH3+ cells
occupied a zone 60 μm wide from the ventricular surface
(Figure 6A). Among these, a subset of PH3+ cells abutting
the ventricular surface showed no Pax6 expression (Figure
6B,C). Furthermore, flow cytometric analyses showed
that, at E7 (HH stage 32), only a small proportion of the
G2/M phase cells (16.2% of total cells) are PH3+ cells
(1.3% of total cells). Thus, most cells with 4n DNA con-
tent, including the majority of Pax6Hi cells, were G2 phase
cells (14.9% of total cells). Among PH3+ M phase cells,
Divergence of Pax6 protein expression in the G2/M phase of the cell cycle Figure 4 (see previous page)
Divergence of Pax6 protein expression in the G2/M phase of the cell cycle. (A) Flow cytometric analyses of BrdU, 
Pax6, and DNA content among E6.5 (HH stage 30) retinal cells after a 20-minute BrdU pulse labeling. Cell density profiles of 
BrdU+ (upper row) and BrdU- (lower row) cells at various post-chase times are shown. The 0 hour point represents the time 
when cells are dissociated after the pulse label and then fixed and processed for flow cytometry. Each data point represents a 
minimum of 30,000 cells analyzed. The x-axis represents DNA content for G0/G1 (2n), S (between 2n and 4n), and G2/M (4n) 
phase cells. (B) Merged flow cytometry profiles for BrdU+ (green) and BrdU- (red) cells at 0, 3, and 6 hours post-BrdU pulse 
labeling. The purple frames subdivide G2/M phase cells (4n) according to Pax6 levels into high (Hi), low (Lo), and negative 
(Neg) categories. Between 0 and 6 hours of chasing, Pax6Hi cells clearly increased, demonstrating the Pax6 level divergence 
when cells enter the G2/M phase. (C) Quantification of Pax6 levels at stage 30 (E6.5) and stage 33/34 (E7.5 to 8) among BrdU+ 
cells that had entered G2/M phase (4n) as shown in the three boxed regions in (B). The percentages of 4n BrdU+ cells with 
Pax6Hi, Pax6Lo, or Pax6Neg levels among total 4n BrdU+ cells at various post-chase times are shown (N = 3; mean ± standard 
error). Asterisks represent P-values between 0 hours and various chase time points: *P < 0.05; **P < 0.01; ***P < 0.001.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Pax6Hi, Pax6Lo and Pax6Neg cells corresponded to 2.3%,
78.5%, and 24.5% of PH3+ cells, respectively (Figure 6D).
We then examined whether G2/M progenitors with no
Pax6 corresponded to committed cone photoreceptors,
which at maturity contain no Pax6. Confocal imaging
revealed that the early cone cell marker Visinin could be
detected in PH3+ cells (Figure 6E–H), suggesting that the
onset of Visinin expression begins during the M phase.
This was further confirmed in dissociated retinal cell cul-
tures, where we detected co-labeling of PH3 with weak
Visinin signals in anaphase progenitors (Figure 6I–L). Fur-
thermore, confocal imaging demonstrated that intensely
Visinin+  cone photoreceptor precursors expressed no
Pax6, whereas cells emerging from the telophase
expressed both low levels of Pax6 and Visinin (Figure 6M–
P). These data suggested that the emergence of the cone
marker Visinin correlated with the down-regulation of
Pax6 in a subset of M phase cells. Therefore, the diver-
gence of Pax6 expression among a subset of progenitors in
G2/M phase of the cell cycle may reflect neuronal fate
specification.
Correlation of Pax6 levels in progenitors in different phases of the cell cycle Figure 5
Correlation of Pax6 levels in progenitors in different phases of the cell cycle. Flow cytometric analyses of Pax6 levels 
among postmitotic cells and cycling progenitor cells at E7 (HH stage 32). (A) Cell density profile of total retinal cells labeled 
with Pax6 and a combination of neuronal markers, including Brn3a, Islet1/2, AP2a, and Visinin. Neuronal marker-positive cells 
(above the purple line) represent G0 cells; and neuronal marker-negative cells (below the purple line) are mostly progenitor 
cells. (B) Cell density profile of total retinal cells labeled with a combination of neuronal markers (same as in (A)), BrdU, and 
Pax6. Gated areas 'a' and 'c' represent postmitotic G0 phase cells; gated area 'b' represents BrdU+ S phase cells; gated area 'd' 
consists of G1, G2, and M phase cells. (C, D) Cell density profiles of G1 and G2/M phase cells (C) (as gated in area 'd') and S 
phase cells (D) (as gated in area 'b' in (B)) according to Pax6 levels and DNA content. In (D), G1 and G2/M cells are shown in 
the background as a reference to S phase cells. (E) Merged flow cytometry profiles of G1 (red), G2/M (green), and S (blue) 
phase progenitor cells according to Pax6 levels and DNA content. Flow cytometry profiles shown in (A, B) were generated 
with >85,000 cells. Numbers within each panel indicate percentage of gated cells among total cells.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Correlation of Pax6 changes in G2/M phase with the emergence of a neuronal marker Figure 6
Correlation of Pax6 changes in G2/M phase with the emergence of a neuronal marker. (A-C) Confocal images of 
Pax6 and PH3 co-labeling at E6.5 (HH stage 30). Boxed region in (A) is shown as Pax6 and PH3 merge (B) or Pax6 alone (C) at 
twofold magnification, where dotted outlines in (C) encircle all PH3+ cells. (D) Flow cytometry profiles of Pax6, PH3, and 
DNA content at E7 (HH stage 32). For both panels the y-axes represent Pax6 levels, while the x-axes indicate the DNA con-
tent. The left panel shows merged distribution profiles of Pax6 (red) and PH3 (green), and the percentage of PH3+ cells among 
total cells is indicated below. The right panel shows cell density distribution with regard to Pax6 and the cell cycle. The per-
centages of Pax6Hi, Pax6Lo, and Pax6Neg cells among total cells are indicated at the right. (E-H) Confocal images of Visinin, PH3, 
and DAPI co-staining at E6.5 (HH stage 30). The boxed region in (E) is shown as Visinin- (F), PH3- (G), or DAPI staining (H) 
alone at twofold magnification. (I-L) Co-labeling for Visinin (J), PH3 (K), DAPI (L), and merge (I) in dissociated E6 retina cells. 
(M-P) Confocal images of Visinin, Pax6, and DAPI co-staining at E6.5 (HH stage 30). The boxed region in (M) is shown as Visi-
nin (N), Pax6 (O), or DAPI staining (P) alone at twofold magnification. Yellow dotted lines encircle Visinin+Pax6Neg cells, 
whereas white dotted lines in (N-P) encircle a pair of cells at the end of the M-phase with weak Pax6 and Visinin signals. 
Arrows indicate co-labeled cells. Arrowheads point to marker-positive but Pax6- cells. vs, ventricular surface. Scale bars: 100 
μm.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Figure 7 (see legend on next page)Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Effects of altering Pax6 levels on proliferation, neuronal 
fate specification, and cell death
In order to determine whether Pax6 expression levels are
critical in the neurogenic progenitor cells, we perturbed
Pax6 expression using small hairpin RNA (shRNA) knock-
down and overexpression in the E4 to E4.5 (HH stages 22
to 24) central retina. A conserved 21-nucleotide region in
the paired domain shared between Pax6 and Pax6(5a) was
selected and cloned downstream of the mouse U6 pro-
moter as a Pax6 shRNA cassette (Figure 7A). In transient
transfection assays in 293T cells, the shRNA targeting Pax6
(Pax6i) showed more than 90% efficiency in knocking
down co-expressed Pax6 protein, but did not affect expres-
sion of the control red fluorescent protein (RFP; Figure
7B). Similarly, E4 (HH stages 23 to 24) primary retinal
cells transfected with Pax6i showed reduced expression of
endogenous Pax6 protein (Figure 7C). This was con-
firmed by quantification, as the Pax6i-transfected popula-
tion displayed a shift from higher to lower Pax6 levels
(Figure 7D). In addition, in retinal cells transfected with
vectors overexpressing Pax6  or Pax6(5a) cDNA, signifi-
cantly higher levels of Pax6 protein compared to endog-
enous levels were detected (Figure 7E).
We next examined the effects of altering Pax6 levels during
chicken retinogenesis using explant cultures. Quantifica-
tion of proliferating cell marker PCNA showed that retinas
transfected with Pax6i  at E4.5 (HH stage 24) reduced
cycling cells from 66.7% to 49.5%, whereas overexpress-
ing Pax6 did not affect the proportion of PCNA+ cells (Fig-
ure 8A,G). In comparison, both Pax6 shRNA knockdown
and Pax6 overexpression caused significant decreases in
overall BrdU incorporation (Figure 8B), suggesting that
Pax6 levels affected the proportion of cells undergoing
DNA synthesis.
We also examined the influence of Pax6 levels on three
major neuronal cell types generated between HH stage 24
and stage 32. Reducing Pax6 by shRNA resulted in a
decrease of Brn3a+ retinal ganglion cells from 4.3% to
1.2% (Figure 8C,G). However, Pax6 overexpression did
not elevate the production of Brn3a+ RGCs (Figure 8C).
Quantification using Visinin showed that reducing Pax6
using shRNA dramatically enhanced cone precursors from
24.6% to 40.5% (Figure 8E,G). Conversely, overexpress-
ing Pax6 caused reduced Visinin+ cone precursor produc-
tion (Figure 8E). The production of AP2α+ amacrine cells
was enhanced when Pax6 was down-regulated and sup-
pressed when Pax6 was elevated (Figure 8D), suggesting
that amacrine interneuron specification was also sensitive
to Pax6 levels. Together, these results demonstrate that
Pax6 expression levels among neurogenic progenitor cells
critically affect both cell proliferation and neuronal fate
decisions (Figure 8F,G).
Since the small eye phenotype associated with Pax6 muta-
tions may potentially be caused by increased cell death in
the retina, we also examined the effects of altering Pax6
expression levels on cell death. In control retinal explants,
activated caspase 3 signals were detected; however, they
were not often associated with green fluorescent protein
(GFP)-positive transfected cells (Figure 9A,B). In contrast,
in retinal explants transfected with the Pax6i  plasmid,
increased caspase 3 signals were detected and they often
corresponded to GFP+ transfectants (Figure 9C,D). The
effects of altering Pax6 expression levels on cell death were
further assessed in monolayer retinal cultures. Compared
to mock transfected samples, Pax6i knockdown increased
caspase 3+ cells from 6.8% to 9.1% (Figure 9E). Overex-
pression of Pax6(5a) but not Pax6 resulted in increased
caspase 3+ cells compared to controls (Figure 9F). There-
fore, decreasing Pax6 and/or Pax6(5a) or increasing
Pax6(5a) resulted in more cell death.
Discussion
In this study, we have analyzed Pax6 protein expression
during the preneurogenic to neurogenic transition and
among neurogenic chicken retinal progenitor cells. We
provide evidence that Pax6 protein levels are highly
dynamic in proliferating progenitors and are coupled with
cell cycle progression. We also demonstrate that Pax6 lev-
Effectiveness of Pax6 knockdown and overexpression Figure 7 (see previous page)
Effectiveness of Pax6 knockdown and overexpression. (A) Schematics show small hairpin RNA (shRNA) target location 
in Pax6 and Pax6 5a and the structure of the U6 shRNA construct (bottom). (B) Western blots show Pax6 shRNA knock-
down in transfected 293T cells. DNAs used are listed on the top and antibodies used are on the left of the blots. U6, control 
vector used to express shRNA; Pax6i, U6 vector expressing shRNA targeting Pax6; Redi1 and Redi2, U6 vectors expressing 
shRNAs targeting red fluorescent protein (RFP). (C) Immunolabeling shows Pax6 protein knockdown in transfected E4.5 (HH 
stage 24) retinal cells after 2 days in vitro (DIV). Pax6i transfected samples showed fewer cells co-expressing green fluorescent 
protein (GFP) and Pax6. (D) Quantification of Pax6 protein signal intensities among U6 vector and U6-Pax6i vector trans-
fected E4.5 retinal cells after 2 DIV. Asterisks represent P-values between the control and the Pax6i samples: *P < 0.05 (N ≥ 4, 
mean ± standard error). (E) Immunofluorescent staining of E5 (HH stage 27) retinal cells transfected with CAG control vector 
and Pax6 or Pax6(5a) overexpression vectors after 2 DIV. Note both Pax6 and Pax6(5a) expression vector-transfected cells 
show higher Pax6 expression levels than endogenous Pax6 levels observed in retinal cells.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Effects of altering Pax6 expression on cell proliferation and fate specification Figure 8
Effects of altering Pax6 expression on cell proliferation and fate specification. Chicken retinal explants were trans-
fected with Pax6 shRNA expression or Pax6 overexpression vectors at E4.5 (HH stage 24). Cell marker assays were per-
formed after 3 days in vitro. Statistically significant sample pairs are indicated with asterisks and specific P-values (N ≥ 4). (A-E) 
Bar graphs showing percentages of cell marker and green fluorescent protein (GFP) double positive cells over total GFP+ trans-
fected cells. (F) Compilation of cell type markers among all transfected GFP+ cells under control and Pax6 perturbation condi-
tions. The mean values were used to generate the graph. (G) Summary of the percentages of cell markers and deviations (N ≥ 
4, mean ± standard error) under controls and Pax6 knockdown or Pax6 overexpression conditions. BrdU, bromodeoxyuridine; 
PCNA, proliferating cell nuclear antigen.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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Effects of altering Pax6 expression on cell death Figure 9
Effects of altering Pax6 expression on cell death. (A-D) Immunofluorescent images of retinal explants transfected at 
E4.5 (HH stage 24) with U6 control (A, B) and U6-Pax6i (C, D) vectors after 2 days in vitro. (A, C) Merged images for green flu-
orescent protein (GFP), activated caspase 3 (Casp3, red), and DAPI. (B, D) Merged images showing GFP+ transfected cells and 
Casp3+ signals. Note that Pax6i-transfected retinas show higher levels of apoptosis than the U6 control. Arrows in (D) indicate 
cells co-labeled for GFP and Casp3. (E, F) Quantification of Casp3+ cells among GFP+-transfected cells in dissociated E5 (HH 
stage 27) retinal cell cultures after 2 days in vitro. Statistically significant data points between the controls and given samples are 
indicated with asterisks and specific P-values (N = 3, mean ± standard error). gcl, ganglion cell layer; vs, ventricular surface.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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els critically influence cell proliferation and cell fate spec-
ification of neurogenic progenitors.
Pax6 is expressed by retinal progenitors throughout devel-
opment. However, our results show that Pax6 protein lev-
els are significantly down-regulated as retinal progenitors
undergo the preneurogenic to neurogenic transition and
initiate production of postmitotic neurons. During the
remainder of retinogenesis, the peripheral margin progen-
itor cells retain a higher level of Pax6 compared to the cen-
tral progenitor cells. How the down-regulation of Pax6
expression is achieved during the preneurogenic to neuro-
genic transition remains unknown, but it may involve sig-
nals that promote cell-intrinsic changes necessary to
enable cell cycle exit and neuronal fate specification. The
differing levels of Pax6 in the peripheral versus central ret-
ina are achieved, in part, at the transcriptional level
through the complex arrays of Pax6 enhancers [17,19].
Our data suggest that translational and/or post-transla-
tional regulation may also contribute to the rapid change
of Pax6 protein levels during the cell cycle. The cellular
distinctions between the central Pax6Lo and peripheral
Pax6Hi progenitors are not well understood. Conditional
ablations of the Pax6 gene in the peripheral retina by Pax6
α-cre and in the central retina by the Chx10-cre both block
expression of proneural genes and limit the pluripotency
of retinal progenitors [40,41]. However, the peripherally
expressed Pax6 also plays a role in suppressing the Crx
gene [41], suggesting either a context-dependent or dos-
age-dependent mechanism. The Pax6 perturbation carried
out in our study focused on the central neurogenic retina,
where the expression of several proneural genes, including
Ath5 and Ngn2, has begun and postmitotic neurons have
accumulated. Thus, our experiments address the impor-
tance of Pax6 regulation among neurogenic progenitors.
We have established by quantitative flow cytometry anal-
ysis that the cycling neurogenic progenitor population
expresses a relatively low level of Pax6, which when per-
turbed interferes with BrdU incorporation. Interestingly,
overexpression of Pax6 resulted in a decreased number of
cells undergoing DNA synthesis, but did not significantly
impact the proportion of PCNA+ cells remaining in the
cell cycle. Since PCNA labels proliferating cells in all
phases of the cell cycle, this result suggests that high Pax6
levels potentially alter cell cycle distribution and/or lead
to cell cycle arrest. Consistent with our observations, stud-
ies in the developing cortex have shown that reducing
Pax6 perturbs cell cycle length and affects the preneuro-
genic to neurogenic transition [30,31]. In addition, activa-
tion of Pax6 or Pax6(5a) above endogenous levels in the
cortical progenitors disrupts cell cycle progression [28].
Live imaging of a tagged Pax6 isoform has revealed that
Pax6p46 is associated with the pericentromeric area of the
chromosomes during M phase, and overexpression of this
isoform causes abnormal mitosis [44]. Our study shows
that low levels of Pax6 are expressed by the majority of
neurogenic progenitors, but progenitor cells residing
within the S phase appear to maintain a more uniformly
low level of Pax6 compared to G1 and G2/M phase cells.
This raises the possibility that the G1 to S phase transition
of neurogenic progenitors may require a narrow range of
Pax6 protein. Further analyses are necessary to determine
the precise cell cycle defects of retinal progenitors with
aberrant levels of Pax6 expression.
Previous findings show that heterozygous Pax6 loss of
function mutations lead to microphthalmia in mice [8-
12], which is primarily due to defects in early eye morpho-
genesis. In transgenic mice carrying multiple copies of
Pax6, the eye morphology and retinogenesis are initially
normal, but RGC axons show dose-dependent projection
defects accompanied by postnatal cell loss [12,13]. This
suggests that Pax6 levels affect RGC differentiation and
survival. Since Pax6 positively regulates transcription of
the proneural gene Math5 required for RGC development
[45], high levels of Pax6 may cause inappropriate Math5
expression, leading to RGC death. Consistent with the
finding that aberrant Pax6 levels cause increased apopto-
sis during cortical development [28], we have detected
increased cell death due to reduced Pax6 or increased
Pax6(5a) levels in the neurogenic retina. These findings
indicate that stringent regulation of Pax6 levels is critical
for cell survival at different stages of eye/retinal develop-
ment.
We have demonstrated that various postmitotic retinal
neurons exhibit distinct Pax6 levels, suggesting that Pax6
expression is readjusted when neurogenic progenitors
become postmitotic, and that Pax6 may, therefore, func-
tion in cell fate determination of progenitors and/or sub-
sequent neuronal differentiation. Our data show that
perturbing Pax6 during chicken retinogenesis impacts cell
fate specification. In close correlation with the contrasting
levels of Pax6 in mature RGCs and cone photoreceptors,
decreasing Pax6 led to reduced RGC and enhanced pho-
toreceptor genesis. Conversely, forced expression of Pax6
suppressed photoreceptor production. However, we did
not detect increased RGC production due to forced Pax6
expression as previously observed in a low density monol-
ayer chicken retinal culture [46]. This might be due to the
progenitors in our retinal explants already expressing suf-
ficient amounts of Pax6 to facilitate RGC fate specifica-
tion. Alternatively, Pax6 overexpression enhances early
neuronal markers but not the more mature RGC marker
Brn3a. The majority of postmitotic amacrine cells express
high levels of Pax6 in the chicken retina. Our results show
that both reducing and elevating Pax6 altered amacrine
production, supporting a requirement for Pax6 in either
specification or differentiation of amacrine interneurons.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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This result is consistent with phenotypes of Pax6 condi-
tional knockout in the more centrally localized progeni-
tors, which also lose their pluripotency [41]. The fact that
both gain and loss of Pax6 function impede amacrine cell
development in the chicken retina suggests that Pax6 is
likely required for amacrine cell fate specification rather
than differentiation, but direct perturbation of Pax6 in
postmitotic amacrine cells is necessary to distinguish
these possibilities.
In this study, we present the first analysis of Pax6 protein
dynamics with regard to the neurogenic cell cycle. We pro-
vide evidence that a subset of neurogenic progenitor cells
begins to display divergent Pax6 protein levels upon
entering into the G2 phase of the cell cycle. This cell cycle-
correlated Pax6 protein level change is more readily
detectable in the later neurogenic retina (Figures 4, 5, and
6). The dramatic changes of Pax6 levels among the subset
of progenitors, coupled with the relatively short G2 phase,
indicate that Pax6 protein in neurogenic progenitors may
be subjected to rapid proteolytic degradation. In addition,
the correlation between decreased Pax6 expression and
the appearance of the neuronal marker Visinin in late M
phase cells suggests that the subset of progenitor cells
showing divergent Pax6 expression in G2/M are likely
those that have committed to certain cell fates. Therefore,
neuronal fate determination is likely to have occurred
prior to the G2 phase of the neurogenic cell cycle, which
produces at least one postmitotic neuron.
Based on our results, we propose that preneurogenic reti-
nal progenitor cells maintain a high level of Pax6
(*Pax6Hi), which by an unknown mechanism undergoes
a substantial down-regulation when cells enter the neuro-
genic phase. Neurogenic progenitors maintain a low level
of Pax6 (Pax6Lo), which is essential for sustaining cell pro-
liferation, survival, and neuronal fate selection. Under the
influence of unidentified extrinsic and/or intrinsic cues, a
subset of progenitors alters their Pax6 levels upon entry
into the G2/M phase in preparation for cell cycle exit.
Postmitotic neurons display distinct cell type-specific lev-
els of Pax6, ranging from high (Pax6Hi) to no Pax6
(Pax6Neg), whereas G1 progenitor cells maintain or regain
the characteristic low level of Pax6 (Pax6Lo) before the G1
to S transition (Figure 10). Results reported here reveal
important functions of Pax6 during the neurogenic phase
of retinal development and the dynamic nature of Pax6
protein regulation within the cell cycle. Future investiga-
tions probing mechanisms that regulate this cell cycle-
dependent expression of Pax6 among progenitor cells will
enhance our understanding of how progenitor prolifera-
tion and fate specification are coordinated.
Conclusion
During the preneurogenic to neurogenic transition, reti-
nal progenitor cells undergo dramatic down-regulation of
Pax6 protein. A low level of Pax6 protein is essential for S
phase entry and normal proliferation of neurogenic pro-
genitors. A subset of neurogenic progenitors rapidly
increase or decrease Pax6 levels in the G2/M phase of the
cell cycle, forecasting cell fate selections prior to G2. The
dynamic regulation of Pax6 protein within the cell cycle is
critical for the expansion and fate specification of neuro-
genic progenitors.
Materials and methods
Chicken embryos
Fertilized White Leghorn chicken eggs were purchased
from Charles River (Wilmington, MA, USA) and were
incubated at 38°C in a rotating humidified incubator.
Embryos were staged (HH stage) according to Hamburger
and Hamilton [47].
Pax6 expression during cell cycle progression and a model of  cell cycle-dependent Pax6 regulation Figure 10
Pax6 expression during cell cycle progression and a 
model of cell cycle-dependent Pax6 regulation. A 
model of dynamic Pax6 expression during retinogenesis is 
depicted. Pax6 protein levels decrease in progenitor cells 
during the transition from the preneurogenic (indicated with 
an asterisk) to the neurogenic stage. Neurogenic progenitors 
express low levels of Pax6 protein, which is essential for 
maintaining the proliferative state, especially the reentry of S 
phase. The cohort of S phase cells contains a relatively uni-
form level of low Pax6. Upon entering into the G2/M phase, 
the neurogenic progenitor population displays more diver-
gent Pax6 levels, with a subset of progenitor cells showing 
increased or decreased Pax6 protein expression depending 
on the developmental stage. Because postmitotic neurons 
contain distinct levels of Pax6 protein, the divergence of Pax6 
expression during the G2/M phase may forecast cell fate 
specification at or prior to the G2 phase of the cell cycle. 
Postmitotic neurons achieve and maintain specific and dis-
tinct levels of Pax6 during differentiation. RGC, retinal gan-
glion cell.Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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DNA constructs
Overexpression constructs were generated by cloning the
human  Pax6  and  Pax6(5a) cDNAs downstream of the
chicken beta actin enhanced cytomegalovirus promoter
(CAG)[48] followed by an internal ribosomal entry site
upstream of the human placental alkaline phosphatase.
For shRNA-mediated knockdown, hairpin sequences spe-
cifically targeting Pax6 or the control RFP message (HcRed
N1; Clonetech, Mountain View, CA, USA) were cloned
downstream of the mouse U6 promoter in the vector pBS/
U6 (U6) [49]. In addition, a cassette containing the CAG
promoter and a nuclear GFP was cloned downstream of
the of U6 shRNA cassette in the same orientation. The set
of specific primers used to generate the shRNAs targeting
Pax6 were: XJY276 (5'GGTCTGTACCAACGATAACAA);
XJY277 (5'AGCTTTGTTATCGTTGGTACAGACC); XJY278
(5'AGCTTTGTTATCGTTGGTACAGACCCTTTTTG);
XJY279 (5'AATTCAAAAAGGGTCTGTACCAACGA-
TAACAA). The two sets of specific primers used to gener-
ate the shRNAs Redi1  and  Redi2  targeting HcRed N1
(Clonetech) were:
Redi1, XJY694 (5'GGCACCGTGAACGGCCACTACTTA),
XJY695 (5'AGCTTAAGTAGTGGCCGTTCACGGTGCC),
XJY696 (5'AGCTTAAGTAGTGGCCGTTCACGGT-
GCCCTTTTTG), XJY697 (5'AATTCAAAAAGGGCACCGT-
GAACGGCCACTACTTA); Redi2, XJY698
(5'GGAGAGAACCACCACCTACGAA), XJY699 (5'AGCTT-
TCGTAGGTGGTGGTTCTCTCC), XJY700 (5'AGCTTTCG-
TAGGTGGTGGTTCTCTCCCTTTTTG), XJY701
(5'AATTCAAAAAGGGAGAGAACCACCACCTACGAA).
Retinal cultures and transfection assays
For transfection of monolayer cells, dissociated HH stage
27 retinal cells were plated on poly-D-lysine coated 8-well
LabTek (Nalge Nunc, Rochester NY, USA) slides at 20,000
cells/mm2, 3 hours prior to Lipofectamine PLUS (Invitro-
gen, Carlsbad, CA, USA) transfection using Pax6 shRNA
knockdown vectors or Pax6 overexpression vectors with a
CAG-nGFP plasmid at 2:1 ratio [50]. For transfection of
retinal tissues, DNA at 2 μg/ml in phosphate-buffered
saline (PBS) was injected into the subretinal space of the
eye at HH stage 24/25. The injected eyes were placed
between paddle electrodes and subjected to five pulses at
10 V/mm for 25 ms with 975-ms intervals using ECM 830
Square Wave Electroporation System (BTX, Holliston,
MA, USA). Central retinas (posterior halves) were dis-
sected from electroporated eyes and cultured on Nucle-
opore membrane discs (Millipore, Billerica, MA, USA)
floating on a retinal culture medium containing an equal
ratio of F12:DMEM (JRH Biosciences, Lenexa, KS, USA),
2% fetal calf serum, 0.2% chicken serum, 10 mM HEPES,
and penicillin/streptomycin at 37°C in 5% CO2 for 72
hours.
Transfection of 293T cells was carried out using Lipo-
fectamine PLUS (Invitrogen) and 0.65 μg of U6-Pax6i,
U6-Redi1, U6-Redi2, or U6-GFP with 0.5 μg of either
RCAS(B)-hPax6 DNA or CMV-HcRedN1 (RFP) as well as
0.35 μg of CAG-nGFP as transfection control. At 48 hours
post-transfection, cells were lysed in RIPA buffer without
deoxycholate, protein extracts were resolved on a 10% Bis-
Tris SDS-PAGE gel using MOPS buffer (Invitrogen), and
transferred onto nitrocellulose membrane. Blots were
probed with antibodies against GFP (1:500; Invitrogen),
HcRedN1 (1:500; Becton Dickenson, Laguna Hills, CA,
USA), Pax6 (1:1,000; Chemicon/Millipore, Billerica, MA,
USA), and followed by secondary antibodies conjugated
with horseradish peroxidase and detected by enhanced
chemiluminescence (ECL plus; Amersham, Piscataway,
NJ, USA).
Immunohistochemistry and imaging
Heads of chicken embryos or retinal explants were fixed in
4% paraformaldehyde in PBS overnight at 4°C, followed
by cryoprotection with 30% sucrose in PBS and embed-
ding in OCT. Coronal sections 20 μm thick were collected
and used for immunolabeling. For BrdU pulse labeling,
the posterior half of HH stage 30 or stage 33 to 34 retinas
were dissected and incubated in the retinal culture
medium supplemented with 20 μm BrdU for 20 minutes,
followed by extensive washes in fresh culture medium
without BrdU, and then further cultured as free floating
explants for designated time periods. Retinal cryosections
labeled with BrdU were treated with 95% formamide in
1× standard sodium citrate (SSC) pH7.4 for 10 minutes at
70°C prior to antibody incubation.
Immunohistochemistry was performed as previously
described [51]. Cryosections or monolayer cells were
incubated with the following primary antibodies: Neuro-
filament 68 (mouse, 1:200; Sigma Aldrich, St. Louis, MO,
USA), Neurofilament 145 (rabbit, 1:500; Chemicon),
Phospho-histone H3 ser28 (rabbit, 1:500; Millipore),
Phospho-histone H3 ser10 (rat monoclonal, 1:250;
Sigma), Pax6 (mouse, 1:10; Developmental Study Hybri-
doma Bank, Iowa City, IA, USA), Pax6 (rabbit, 1:500;
Chemicon and Covance, Princeton, NJ, USA), PCNA
(mouse, 1:200; Sigma), Brn3a (mouse, 1:200; Chemi-
con), AP2α (mouse, 1:5; DSHB), Islet 1/2 (mouse clone
39.4D5, 1:10; DSHB), Visinin (mouse, 1:50; DSHB), acti-
vated caspase 3 (rabbit, 1:250; Upstate/Millipore), BrdU
(mouse, 1:5; Amersham), and GFP (mouse monoclonal
and rabbit polyclonal; Invitrogen). Sections were then
incubated with either biotinylated secondary antibodies
followed by horseradish peroxidase detection (Vector
Laboratories, Burlingame, CA, USA) using 3,3'-diami-
nobenzidine (Sigma), or appropriate secondary antibod-
ies conjugated to Alexa 488, 568, 594, or 647
(Invitrogen). For nuclear staining, 1 mg/ml of 4',6-dia-Neural Development 2009, 4:32 http://www.neuraldevelopment.com/content/4/1/32
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midino-2-phenylindole (DAPI; Roche, Palo Alto, CA,
USA) was used. Epifluorescent and DIC images were cap-
tured using a Nikon E800 microscope equipped with a
SPOTII digital camera. Confocal optic sections 1 μm thick
were obtained using a Zeiss LSM 410 confocal laser-scan-
ning system with a Zeiss Axiovert 135M microscope, or a
Leica TCS SP MP confocal microscope.
Flow cytometry
The anterior (st25 analysis) and posterior halves of retinas
were dissected and collected in Hank's buffer saline solu-
tion (HBSS+; Invitrogen). Retinas were washed in HBSS
without Mg+ and Ca+ (HBSS-; Invitrogen) and incubated
with 0.1% trypsin (Sigma) at 37°C for 10 minutes. Soy-
bean trypsin inhibitor (Sigma) at a final concentration of
0.1 mg/ml or chicken serum (Sigma) to 10% of total vol-
ume was added to stop trypsin, followed by addition of
DNaseI (Sigma) to 50 mg/ml and trituration to obtain
single cell suspensions. Single cell suspensions were fixed
in 2% paraformaldehyde in PBS for 30 minutes, washed
with HBSS+, followed by 0.1% Triton-X in HBSS+ incuba-
tion prior to staining with primary and secondary anti-
bodies as described above with washes in between. Anti-
PCNA and anti-BrdU antibody labeled cells were also
treated with 2 N and 1 N HCl, respectively, prior to anti-
body labeling. Cells were filtered and collected using a
tube with a 35 mm nylon mesh cap (BD Biosciences/Fal-
con, San Jose, CA, USA) before flow cytometry analyses
using an LSR flow cytometer (BD Biosciences).
Quantification of cell markers and statistical analysis
Quantification of various cell markers for dissociated ret-
inal cells was performed by counting non-overlapping
fields through the microscope directly or by analyzing
acquired digital images using ImagePro PLUS software
(Media Cybernetics, Bethesda, MD, USA). For each sam-
ple, a minimum of 200 marker-positive cells or the entire
7-mm diameter well was counted. Quantification of dis-
sociated retinal cells by FACS was performed using FlowJo
v5.7.2 according to the manufacturer's guidelines (Ash-
land, OR, USA). For each sample, a minimum of 30,000
cells was analyzed. Student t-test was applied to data sets
where P < 0.05 is considered statistically significant. Data
were presented as mean ± SEM.
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